711 bet bonus code philippines today

Shaken Pep Guardiola admits title race could be over NEXT WEEK as ‘fragile’ Man City suffer fifth defeat in a rowBEREA, Ohio (AP) — Myles Garrett didn't know he had joined a prestigious list of defensive stars last week until one of his biggest fans pointed it out to him. “My dad was hyped about it,” he said. For good reason. With three sacks last week in Cleveland's 24-19 win in prime time over the Pittsburgh Steelers, Garrett became the seventh player to reach double-digit sacks in seven straight seasons since the stat became official in 1982. The others: Lawrence Taylor (1984-90), Reggie White (1985-93), Bruce Smith (1992-98), John Randle (1992-99), DeMarcus Ware (2006-12) and Jared Allen (2007-13). All of them is in the Hall of Fame except for Allen. “Hall of Famer,” Garrett said in praising the retired Minnesota Vikings edge rusher, who is again on the doorstep of induction as a semifinalist for the fifth straight year. Garrett is on track to get his own bronze bust one day in Canton, but until then, he's humbled to be in such elite company. “Guys I looked up to when I started my journey into this game,” said Garrett, who tries to bolster his resume on Monday night when the Browns (3-8) visit the Denver Broncos (7-5). “It’s absolutely amazing to be amongst those guys, not just looking up at them but looking side to side and standing amongst them. "So I want to continue to find myself on those lists and hopefully stand alone at the end of the day.” He's on his way. The NFL's reigning Defensive Player of the Year is having another monster season but probably not getting the recognition he deserves as the Browns, upended by continuous quarterback issues, have fallen way short of expectations. Garrett used the national TV platform against the Steelers to remind any detractors of his greatness. He sacked Russell Wilson three times, forced a fumble and outplayed Pittsburgh's T.J. Watt, the player to whom he is most often compared. The Garrett vs. Watt debate went to another level in February. On the day Garrett received his DPOY award, second-place finisher Watt seemed to take a shot at the Browns star by posting “Nothing I'm not used to” on social media. Those comments stuck with Garrett, who following the win over Pittsburgh — and Watt being held without a sack — didn't hold back in declaring himself the league's best pass rusher. “I wanted to make it known that I’m the guy, I’m the No. 1 edge defender,” Garrett said. It was an unusual boast from Garrett, who was asked why he felt he needed to express himself. “Because part of my journey of being the best player that I can be is I think I can be the best player that there is currently,” he said. ”So I have to live up to those expectations I have for myself. That’s just on the road to be the player that I want to be.” Garrett's unrelenting drive is what sets him apart. Although he'll enter Monday's game with 98 1/2 sacks and can become just the fifth player to reach 100 in his first eight seasons, joining White, Ware, Allen and Watt, it's not enough. “I still took too long,” said Garrett, who can become the first to do it before turning 29. “It’d have been tough to catch Mr. White, but hopefully this next however many number will come quicker than the first 100. So we’ll go out there and we’ll do what I do and try to take it up a notch.” Browns defensive coordinator Jim Schwartz marvels at Garrett's output despite double- and triple-team blocking. “He just continues to do stuff,” Schwartz said. “His production is so high, even though he’s a marked man, even though every game plan starts with, ‘Don’t let 95 wreck the game,’ and he still finds a way to wreck games.” Schwartz doesn't need to see any lists to know Garrett belongs among the best to ever rush a quarterback. “Yes, he does,” Schwartz said. "I think he’s just starting to hit his prime. I think he still has a lot left in front of him. The sky is the limit as far as he goes. And when it’s all said and done, maybe you’re comparing other people to him. That should probably be a goal for him.” AP NFL: https://apnews.com/hub/nfl

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Five things to know about Panama Canal, in Trump's sightsThe Sunday Interview: WA MP Stephen Dawson discusses being an openly gay politician

GB's Marchant crashes into London velodrome crowdMUNICH (AP) — Harry Kane is the quickest player to score 50 goals in the Bundesliga after scoring a hat trick on his 43rd appearance on Friday. Kane’s three goals – including two penalties – gave Bayern a 3-0 win over Augsburg , stretching the Bavarian powerhouse’s lead to eight points ahead of the rest of the 11th round. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

UCF will attempt to shake off a dreadful offensive performance when it collides with LSU on Sunday afternoon in the third-place game of the Greenbrier Tip-Off in White Sulphur Springs, W.Va. The Knights (4-1) couldn't get anything going against No. 19 Wisconsin on Friday, going 21-for-62 from the field (33.9 percent) and just 2-for-17 from 3-point range (11.8 percent) en route to an 86-70 loss. Jordan Ivy-Curry finished with 13 points while Keyshawn Hall and Dior Johnson added 11 apiece for UCF, which never led and fell behind by as many as 23. Knights coach Johnny Dawkins is hoping that his team's struggles don't carry over into the meeting with the Tigers (4-1). "We have to do better offensively," Dawkins said. "We have to space the floor better. We have to balance our offense between our perimeter and our bigs. Those are things that we didn't do consistently (on Friday)." LSU also needs to clean things up after committing 15 turnovers in a 74-63 setback against Pitt on Friday. Tigers forward Jalen Reed doesn't believe giving the ball away will be a lingering issue. "I feel like a lot of our turnovers were more on us than them," Reed said. "I feel like a lot of the turnovers were careless, but we're a better team than that and I feel like we'll take care of the ball better moving forward." Reed and Vyctorius Miller each posted 14 points in the loss to the Panthers, with Reed also hauling in seven rebounds. Cam Carter chipped in 11 points. Carter is putting up a team-leading 16.4 points per game. Jordan Sears (12.0 points per game), Reed (11.0) and Miller (10.2) also have scoring averages in double figures. Ivy-Curry (16.8 points per game), Hall (16.2) and Darius Johnson (13.0) have been leading the way for UCF. Sunday marks the first-ever meeting between the Knights and Tigers. --Field Level Media

Six healthy habits to add to your working dayGREENVILLE, S.C. (AP) — Pjay Smith Jr. scored 23 points as Furman beat Princeton 69-63 on Saturday. Smith also added eight rebounds and four steals for the Paladins (9-1). Garrett Hien scored 10 points while going 5 of 10 and 0 of 4 from the free-throw line and added seven rebounds. Nick Anderson shot 3 for 9 from beyond the arc to finish with nine points. The Tigers (7-4) were led by Xaivian Lee, who posted 16 points, seven rebounds and five assists. Princeton also got 13 points and four assists from Dalen Davis. Caden Pierce also had 11 points and four steals. NEXT UP Up next for Furman is a Saturday matchup with South Carolina State at home, and Princeton hosts Monmouth on Tuesday. The Associated Press created this story using technology provided by and data from .UCF will attempt to shake off a dreadful offensive performance when it collides with LSU on Sunday afternoon in the third-place game of the Greenbrier Tip-Off in White Sulphur Springs, W.Va. The Knights (4-1) couldn't get anything going against No. 19 Wisconsin on Friday, going 21-for-62 from the field (33.9 percent) and just 2-for-17 from 3-point range (11.8 percent) en route to an 86-70 loss. Jordan Ivy-Curry finished with 13 points while Keyshawn Hall and Dior Johnson added 11 apiece for UCF, which never led and fell behind by as many as 23. Knights coach Johnny Dawkins is hoping that his team's struggles don't carry over into the meeting with the Tigers (4-1). "We have to do better offensively," Dawkins said. "We have to space the floor better. We have to balance our offense between our perimeter and our bigs. Those are things that we didn't do consistently (on Friday)." LSU also needs to clean things up after committing 15 turnovers in a 74-63 setback against Pitt on Friday. Tigers forward Jalen Reed doesn't believe giving the ball away will be a lingering issue. "I feel like a lot of our turnovers were more on us than them," Reed said. "I feel like a lot of the turnovers were careless, but we're a better team than that and I feel like we'll take care of the ball better moving forward." Reed and Vyctorius Miller each posted 14 points in the loss to the Panthers, with Reed also hauling in seven rebounds. Cam Carter chipped in 11 points. Carter is putting up a team-leading 16.4 points per game. Jordan Sears (12.0 points per game), Reed (11.0) and Miller (10.2) also have scoring averages in double figures. Ivy-Curry (16.8 points per game), Hall (16.2) and Darius Johnson (13.0) have been leading the way for UCF. Sunday marks the first-ever meeting between the Knights and Tigers. --Field Level Media

Royce Value Trust Inc. (NYSE:RVT) Shares Acquired by Prospera Financial Services Inc

4 things we learned from Jaylen Brown’s Men’s Health cover profileRich countries' promise of $300 billion a year in climate finance brought fury at talks in Baku from poor nations that found it too paltry, but it also shows a shift in global political realities. The two-week marathon COP29 climate conference opened days after the decisive victory in the US presidential election of Donald Trump, a sceptic both of climate change and foreign aid.

CIBC Asset Management Inc bought a new stake in Ryan Specialty Holdings, Inc. ( NYSE:RYAN – Free Report ) during the third quarter, HoldingsChannel.com reports. The firm bought 3,478 shares of the company’s stock, valued at approximately $231,000. Several other institutional investors have also recently bought and sold shares of the business. Principal Financial Group Inc. grew its position in Ryan Specialty by 148.9% during the 3rd quarter. Principal Financial Group Inc. now owns 851,704 shares of the company’s stock worth $56,545,000 after acquiring an additional 509,548 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Ryan Specialty by 132.2% during the second quarter. Bank of New York Mellon Corp now owns 836,209 shares of the company’s stock worth $48,425,000 after buying an additional 476,126 shares during the last quarter. 2Xideas AG bought a new stake in shares of Ryan Specialty during the 1st quarter valued at about $19,765,000. Driehaus Capital Management LLC acquired a new stake in shares of Ryan Specialty during the 2nd quarter worth approximately $16,313,000. Finally, Rhumbline Advisers increased its stake in Ryan Specialty by 153.9% in the second quarter. Rhumbline Advisers now owns 283,952 shares of the company’s stock valued at $16,444,000 after purchasing an additional 172,101 shares in the last quarter. Institutional investors and hedge funds own 84.82% of the company’s stock. Insider Activity In other news, EVP Mark Stephen Katz sold 14,790 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $71.39, for a total transaction of $1,055,858.10. Following the completion of the transaction, the executive vice president now directly owns 12,386 shares of the company’s stock, valued at approximately $884,236.54. This represents a 54.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Also, Director Nicholas Dominic Cortezi sold 5,375 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $64.73, for a total value of $347,923.75. Following the completion of the sale, the director now directly owns 2,685 shares in the company, valued at $173,800.05. The trade was a 66.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last 90 days, insiders sold 22,490 shares of company stock valued at $1,553,977. 11.10% of the stock is currently owned by company insiders. Wall Street Analysts Forecast Growth Check Out Our Latest Analysis on Ryan Specialty Ryan Specialty Price Performance Shares of NYSE:RYAN opened at $73.52 on Friday. The company’s fifty day moving average is $69.06 and its 200 day moving average is $62.51. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 2.40. Ryan Specialty Holdings, Inc. has a 52 week low of $41.49 and a 52 week high of $74.53. The stock has a market cap of $19.25 billion, a PE ratio of 95.48, a PEG ratio of 1.60 and a beta of 0.62. Ryan Specialty ( NYSE:RYAN – Get Free Report ) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.41 EPS for the quarter, hitting the consensus estimate of $0.41. The firm had revenue of $604.69 million for the quarter, compared to the consensus estimate of $602.04 million. Ryan Specialty had a return on equity of 47.90% and a net margin of 10.31%. The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 earnings per share. Research analysts anticipate that Ryan Specialty Holdings, Inc. will post 1.8 earnings per share for the current year. Ryan Specialty Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 26th. Shareholders of record on Tuesday, November 12th will be given a $0.11 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $0.44 annualized dividend and a yield of 0.60%. Ryan Specialty’s payout ratio is currently 57.14%. Ryan Specialty Company Profile ( Free Report ) Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter. See Also Want to see what other hedge funds are holding RYAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ryan Specialty Holdings, Inc. ( NYSE:RYAN – Free Report ). Receive News & Ratings for Ryan Specialty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryan Specialty and related companies with MarketBeat.com's FREE daily email newsletter .

Christopher Nolan’s Next Movie Gets Title, Is a ‘Mythic Action Epic’ By has officially been announced by . In a surprise piece of news, the film will be an adaptation of a literary classic. What is the title of Christopher Nolan’s next movie? In an announcement on social media, Universal Pictures revealed that Nolan’s next movie will be an adaptation of Homer’s The Odyssey. The film is described as a “mythic action epic” that’s been shot across the world and will utilize “brand new IMAX film technology.” “Christopher Nolan’s next film The Odyssey is a mythic action epic shot across the world using brand new IMAX film technology,” reads Universal’s post. “The film brings Homer’s foundational saga to IMAX film screens for the first time and opens in theaters everywhere on July 17, 2026.” Christopher Nolan’s next film ‘The Odyssey’ is a mythic action epic shot across the world using brand new IMAX film technology. The film brings Homer’s foundational saga to IMAX film screens for the first time and opens in theaters everywhere on July 17, 2026. The Odyssey is one of two ancient Greek epic poems attributed to Homer, a Greek poet who is also credited as the author of the Iliad, and who is often seen as one of the most influential and important authors in human history. The Odyssey follows the story of the Greek hero Odysseus, king of Ithaca, as he journeys home after the Trojan War. Presumed dead, Odysseus’ wife Penelope and son Telemachus contend with various suitors who compete for Penelope’s hand in Odysseus’ absence. The Odyssey is thought to have been written sometime in the 8th or 7th century BC, and is one of the most important works of in literary history. Previously, it was announced that , , , and would all also star in the upcoming project. Early reports suggest that Pattinson, Damon, Holland, and Hathaway will make up “the core leads” of the movie. Lupita Nyong’o and Zendaya, both of whom were , will also have supporting roles in some degree, as will . Nolan’s The Odyssey will release in the United States theaters on July 17, 2026, from Universal Pictures. Anthony Nash has been writing about games and the gaming industry for nearly a decade. When he’s not writing about games, he’s usually playing them. You can find him on Twitter talking about games or sports at @_anthonynash. Share article

PENDLETON – The start was sluggish, but the finish was exactly what the Pendleton Heights Arabians needed against rival Mount Vernon on Saturday afternoon. The Class 4A Arabians opened their Hoosier Heritage Conference matchup shooting 0-for-7 on Joe Buck Court before finding their rhythm on defense to build a double-digit advantage by halftime and win big, 59-37. “We came out a little bit slow. We just had to get some energy into it, and once we did, we really started getting into it as a team,” PH sophomore center Adah Hupfer said. “Once we got there, it was up from there.” Hupfer finished with a double-double, adding 10 rebounds to her team-high 16 points, three blocks and two steals. Hupfer shot 12-of-12 from the free-throw line, pouring in 12 points in the first half to help the Arabians pull in front 30-19 by the break. “Obviously, they’re one of our rival teams -- conference, sectional and everything -- and we just have to go out there and compete,” Hupfer said. “I think this is big for us going into (Class 4A No. 2) HSE on Tuesday and going into some harder games, competing against a team that’s beat some teams that we’ve lost to this season. I think it’s a good win against a rival team, so it means a lot.” Any time the Arabians (5-4, 2-1 HHC) and Marauders (7-3, 0-1) clash, records typically aren’t a factor, as both rivals’ competitiveness elevates. Saturday was no exception, as the young, inexperienced Marauders tied the game twice in the first quarter at 9-9 and 11-11 before a 9-0 Arabians’ run in the second quarter created a 26-14 cushion. “You know when Pendleton and Mount Vernon get together, it’s going to be a tough, hard-fought game. We knew that, and we didn’t come out with the intensity we looked for. We talked about our struggles on Saturday afternoons, and I got into them a little bit,” PH coach Nick Rogers said. “After that, I thought we were much better defensively.” The Arabians’ pressure defense forced 12 first-half turnovers and nearly a dozen more in the second half, which provided PH with easy transition baskets and key stops. “If we can control pace and can do what we do instead of falling into what everyone else wants us to do, then we can be pretty good,” Mount Vernon coach Julie Shelton said. “When four out of your seven players are freshmen, that’s a learning curve. We can’t give them 10 points on turnovers at the top of the key. It just can’t happen. The offense sputtered, and we gave them easy baskets.” PH senior Kaycie Warfel matched Hupfer with a team-high 16 points while adding four steals, three assists and two rebounds. Warfel injured her left leg during a collision late in the third quarter, but she returned to the court in the fourth and ended PH’s decisive 11-2 run with a layup that put the Arabians ahead 52-32. “Hupfer and Warfel played really well. They had a good game, and they’re a good team,” Shelton said. “They have a lot of pieces back that have played a lot of years. I just feel like the experience is what happened. Once they got the lead, their experience just carried them, and ours was panic, and then we turned the ball over more.” Mount Vernon freshman Zoey Wood posted a game-high 23 points on 9-of-14 shooting. The shifty 5-foot-5 guard recorded five steals and went 4-for-4 from the foul line. Fellow frosh Delani Williams added nine points and four rebounds for the Marauders. The Arabians countered Mount Vernon’s youthful surge with depth, as junior Olivia Jones provided 10 points, four rebounds and three assists on 4-of-6 shooting from the floor. She buried a pair of PH’s four 3-pointers. Junior Mamie Trout had five points, four rebounds and two steals on 5-of-6 shooting, while senior Emma Roberts had three steals and two points. Sophomore Aubree Warfel chipped in four points and four rebounds. Senior Aubriana Gray and junior Avry Miller each had three points. The Arabians converted 20-of-22 free throws compared to Mount Vernon’s 8-of-10. PH outrebounded MV 28-16, with 14 offensive boards offering the Arabians’ second-chance opportunities. “Boy, was it ugly on the offensive end. Not a lot of execution, and we definitely need to get better in that regard, but it was a good win,” Rogers said. “(Free throws) went much better. That’s why we lost to Jennings County (last Saturday). We were 20-of-22 from the line today. You’re not going to win a lot of games being 4-of-17 like we were in Jennings County, so that was a point of emphasis, and we executed it.” The Arabians head to Hamilton Southeastern on Tuesday before resuming HHC play on Thursday at home against Delta.